Janssen, a unit of Johnson & Johnson, announced this week that the European Commission has approved its ustekinumab (Stelara) for the treatment of moderate to severe ulcerative colitis. Also approved in the European Union to treat plaque psoriasis, psoriatic arthritis, and Crohn disease, the biologic is the first available therapy that targets the interleukin-12 and -23 pathway.
Janssen, a unit of Johnson & Johnson, announced this week that the European Commission has approved its ustekinumab (Stelara) for the treatment of moderate to severe ulcerative colitis (UC). Also approved in the European Union to treat plaque psoriasis, psoriatic arthritis, and Crohn disease, the biologic is the first available therapy that targets the interleukin-12 and -23 pathway.
“Today marks a significant milestone in the treatment of ulcerative colitis,” said Jan Wehkamp, MD, vice president and gastroenterology disease area leader of Janssen Research & Development, LLC, in a statement. “Many hundreds of thousands of people in Europe struggle with one of the 2 types of inflammatory bowel disease—Crohn disease and ulcerative colitis—and are in urgent need of effective treatment options. Ustekinumab has been available to people with Crohn disease since it was approved in 2016, and thanks to the patients who enrolled in the UNIFI clinical trial program and their willingness to participate, we are delighted it will now be available to people with ulcerative colitis, offering them a chance of durable remission and relief from the often painful and debilitating symptoms.”
Approval in the new indication was based on data from the phase 3 UNIFI trial. In the trial, 961 patients with UC were randomized to receive either a single intravenous dose of placebo, 130 mg of ustekinumab, or a weight-tiered dose of ustekinumab.
Evaluation at week 8 showed that 15.6% of patients receiving 130 mg ustekinumab and 15.5% of patients receiving a weight-tiered dose achieved clinical remission, compared with 5.3% of patients receiving placebo (P <.001).
Through week 8, adverse events (AEs), serious AEs, and infections were reported in similar proportions across all 3 groups. There were no malignancies, opportunistic infections, or tuberculosis infections reported.
A further maintenance study of 44 weeks included 523 patients with UC who were in clinical remission after the 8-week study. Patients were randomized to receive placebo or a subcutaneous dose of 90 mg of ustekinumab every 8 weeks or every 12 weeks. In this study, 43.8% and 38.4%, respectively, of the patients in the 2 ustekinumab groups were in clinical remission at week 44 (P <.001) versus 24.0% of the placebo group (<.002)
As ustekinumab advances with its new indication, it also faces the specter of biosimilar competition. Alvotech is developing a biosimilar, which it plans to market with partner Fuji Pharma in Japan, and NeuClone announced earlier in 2019 that it will start a phase 1 clinical trial of its biosimilar, which it is developing with the Serum Institute of India, later this year.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.